1-(1-nicotinoylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea | 1169826-77-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(1-nicotinoylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea
• 英文别名: 1-[1-(pyridine-3-carbonyl)piperidin-4-yl]-3-[4-(trifluoromethoxy)phenyl]urea
• CAS: 1169826-77-0
• 化学式: C₁₉H₁₉F₃N₄O₃
• 分子量: 408.38
• InChiKey: VZQKXLOSWIHURY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS
  申请人：Webb Hsu Heather K.

  公开号：US20090270452A1

  公开（公告）日：2009-10-29

  Disclosed herein are compounds, compositions, and methods for enhancing smooth muscle function in a subject by administration of soluble epoxide hydrolase inhibitors and for treating subjects with smooth muscle disorders including erectile dysfunction, overactive bladder, uterine contractions and irritable bowel syndrome.

  本文揭示了一种通过给予可溶性环氧化物水解酶抑制剂来增强受试者平滑肌功能的化合物、组合物和方法，并用于治疗患有平滑肌障碍的受试者，包括勃起功能障碍、膀胱过度活跃、子宫收缩和肠易激综合征。
• USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY VASCULAR DISEASES
  申请人：Wang Yi-Xin

  公开号：US20100063583A1

  公开（公告）日：2010-03-11

  Disclosed herein are compositions and methods for treating inflammatory vascular diseases. Examples of inflammatory vascular disease include, but are not limited to, in-stent stenosis, coronary arterial diseases (CAD), angina, acute myocardial infarction, acute coronary syndrome, chronic heart failure (CHF), peripheral arterial occlusive diseases (PAOD), critical limb ischemia (CLI), cardiac, kidney, liver and intestinal ischemia, renal failure, cardiac hypertrophy, atherosclerosis, abdominal aortic aneurysm, vasculitis, carotid artery stenosis.

  本文公开了治疗炎症性血管疾病的组合物和方法。炎症性血管疾病的例子包括但不限于支架内狭窄、冠状动脉疾病（CAD）、心绞痛、急性心肌梗死、急性冠状动脉综合症、慢性心力衰竭（CHF）、周围动脉闭塞性疾病（PAOD）、严重肢体缺血（CLI）、心脏、肾脏、肝脏和肠道缺血、肾功能衰竭、心肌肥大、动脉粥样硬化、腹主动脉瘤、血管炎、颈动脉狭窄等。
• SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS
  申请人：Wang Yi-Xin (Jim)

  公开号：US20090197916A1

  公开（公告）日：2009-08-06

  Compounds, compositions, and methods for inhibiting the onset of metabolic syndrome and treating related disorders in a subject in need of such therapy are disclosed.

  本发明公开了一种化合物、组合物和方法，用于抑制代谢综合征的发生并治疗需要该疗法的相关疾病的受体。
• Soluble epoxide hydrolase inhibitors
  申请人：Aavula Bhasker R.

  公开号：US20090270382A1

  公开（公告）日：2009-10-29

  Disclosed are amide, thioamide, urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, and diabetic-related diseases.

  本发明涉及抑制可溶性环氧酯水解酶（sEH）的酰胺，硫酰胺，脲和硫脲化合物及其组合物和组合物的制备方法，以及使用这些化合物和组合物治疗患者的方法。这些化合物，组合物和方法对于治疗各种sEH介导的疾病，包括高血压，心血管，炎症和糖尿病相关疾病非常有用。
• SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION
  申请人：Aavula Bhasker R.

  公开号：US20090247521A1

  公开（公告）日：2009-10-01

  The present invention generally relates to methods useful for a therapy using a class of urea or amide compounds and related compositions, wherein the compound is a soluble epoxide hydrolase inhibitor, for treating and ameliorating the symptoms of diseases related to endothelial dysfunction.